Related Experiment Video
Updated: Jan 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A
Félix Gutiérrez1,2,3,4, Marta Fernández-González1,3,4, Christian Ledesma1,4
1Infectious Diseases Unit, Hospital General Universitario de Elche, Elche, Spain.
Abstract:
In a case series of 13 individuals with historical rilpivirine (RPV) resistance-associated mutations, predominantly E138A, long-acting cabotegravir/rilpivirine (CAB/RPV) maintained suppression over a median 24-month follow-up. Twelve were virologically suppressed at switch. No virological failures occurred, supporting cautious CAB/RPV use in selected patients with remote or polymorphic mutations.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Subviral Agents
Viruses with RNA Genomes

